Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
lunedì, ottobre 05
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Sarepta Therapeutics Inc
SRPT
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$17.50
-0.07
-0.4%
Ult. Agg.: Oct 2, 4:32 PM
$17.50
-0.07
-0.4%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Sarepta Therapeutics Financials
Sarepta Therapeutics (SRPT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Sarepta Therapeutics Q2 Adj. EPS $0.64 Beats $0.26 Estimate, Sales $401.300M Beat $364.343M Estimate
Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $0.64 per share which beat the analyst consensus estimate of $0.26 by 146.15 percent. This is a 68.32 percent decrease over earnings of $2.02 per share
Benzinga Newsdesk
Earnings Scheduled For May 6, 2026
Benzinga Insights
PRO
Sarepta Therapeutics Q1 Adj. EPS $3.16 Beats $0.99 Estimate, Sales $730.803M Beat $474.155M Estimate
Benzinga Newsdesk
Sarepta CEO To Jump Ship After 'Tumultuous' Year
Sarepta stock drops after a wider loss, Elevidys sales fall 33%, and CEO retirement plans add fresh uncertainty for investors.
Vandana Singh
PRO
Sarepta Therapeutics Q4 Adj. EPS $(3.58) Misses $(1.31) Estimate, Sales $442.934M Beat $391.924M Estimate
Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly losses of $(3.58) per share which missed the analyst consensus estimate of $(1.31) by 172.45 percent. This is a 288.42 percent decrease over earnings of $1.90 per
Benzinga Newsdesk
Earnings Scheduled For February 25, 2026
Benzinga Insights
